Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis

New drugs against Mycobacterium tuberculosis are urgently needed to deal with the current global TB pandemic. We report here on the discovery of a series of arylvinylpiperazine amides (AX-35 to AX-39) that represent a promising new family of compounds with potent in vitro and in vivo activities agai...

Full description

Bibliographic Details
Main Authors: Caroline S. Foo, Andréanne Lupien, Maryline Kienle, Anthony Vocat, Andrej Benjak, Raphael Sommer, Dirk A. Lamprecht, Adrie J. C. Steyn, Kevin Pethe, Jérémie Piton, Karl-Heinz Altmann, Stewart T. Cole
Format: Article
Language:English
Published: American Society for Microbiology 2018-10-01
Series:mBio
Subjects:
QcrB inhibitor
cytochrome bc1 oxidase
cytochrome bd oxidase
mycobacterial diseases
mycobacterial respiration
tuberculosis
Online Access:https://doi.org/10.1128/mBio.01276-18

Internet

https://doi.org/10.1128/mBio.01276-18

Similar Items